Deutetrabenazine
12 NDCs across 1 manufacturer|0 Generic,12 Brand
Deutetrabenazine is used to treat chorea and tardive dyskinesia, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Apr 3, 2017, and the first generic was approved Dec 26, 2024. In 2024, Medicare Part D spent $1.7 billion on Deutetrabenazine across 245,000 claims for 31,000 beneficiaries.
Deutetrabenazine is available as 12 NDCs from 1 manufacturer (0 generic, 12 brand), with NADAC prices from $83.30 to $501.99 per EA — the most expensive product costs about 6.0× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
12
0G / 12B
Manufacturers
1
competing in market
Price Spread
$83.30 – $501.99
per EA
7d Activity
avg -0.1% WoW · of 12 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing DEUTETRABENAZINE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
AUSTEDO XR 48 MG TABLET | $501.9926 per EA | +0.01% |
AUSTEDO XR 42 MG TABLET | $499.9053 per EA | +0.06% |
AUSTEDO XR 36 MG TABLET | $418.5464 per EA | -0.46% |
AUSTEDO XR 30 MG TABLET | $333.0514 per EA | -0.07% |
AUSTEDO XR 24 MG TABLET | $250.8413 per EA | -0.19% |
AUSTEDO XR 18 MG TABLET | $250.7850 per EA | -0.12% |
AUSTEDO XR TITR(12-18-24-30 MG) | $249.3230 per EA | — |
AUSTEDO XR 12 MG TABLET | $166.9328 per EA | +0.05% |
AUSTEDO 12 MG TABLET | $125.2350 per EA | -0.16% |
AUSTEDO 9 MG TABLET | $93.9598 per EA | -0.21% |
AUSTEDO XR 6 MG TABLET | $83.6009 per EA | -0.15% |
AUSTEDO 6 MG TABLET | $83.2986 per EA | -0.13% |
Frequently Asked Questions
What is Deutetrabenazine used to treat?
Deutetrabenazine is used to treat chorea and tardive dyskinesia, per the National Library of Medicine's MED-RT classification.
When did Deutetrabenazine become available as a generic?
FDA approved the first generic Deutetrabenazine (ANDA) on Dec 26, 2024.
How much does Medicare spend on Deutetrabenazine?
In 2024, Medicare Part D spent $1.7 billion on Deutetrabenazine across 245,000 claims for 31,000 beneficiaries.
How many Deutetrabenazine products are on the market?
The Deutetrabenazine drug market contains 12 NDCs from 1 manufacturer — 0 generic and 12 brand products.
What is the price range for Deutetrabenazine?
NADAC reference prices for Deutetrabenazine range from $83.2986 to $501.9926 per EA — the most expensive product costs about 6.0× the cheapest.
Which manufacturers make Deutetrabenazine?
1 manufacturer lists Deutetrabenazine in NADAC. Ranked by number of NDCs, the largest are Teva Neuroscience, Inc. (12).
How has the price of Deutetrabenazine changed recently?
Over the past 7 days, 3 Deutetrabenazine NDCs rose and 8 fell, with a market-wide average change of -0.1%.